CELON PHARMA S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.78 PLN | -1.47% |
|
-1.47% | -4.40% |
| Sales 2023 * | 218M 53.9M | Sales 2024 * | 249M 61.56M | Capitalization | 755M 187M |
|---|---|---|---|---|---|
| Net income 2023 * | -16M -3.96M | Net income 2024 * | -20M -4.95M | EV / Sales 2023 * | 3.18 x |
| Net cash position 2023 * | 61.77M 15.29M | Net cash position 2024 * | 34.07M 8.43M | EV / Sales 2024 * | 2.9 x |
| P/E ratio 2023 * |
-55.8
x | P/E ratio 2024 * |
-92.4
x | Employees | 513 |
| Yield 2023 * |
0.61% | Yield 2024 * |
0.64% | Free-Float | 41.19% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.47% | ||
| 1 week | -1.47% | ||
| Current month | -2.25% | ||
| 1 month | -1.34% | ||
| 3 months | -3.27% | ||
| 6 months | -2.25% | ||
| Current year | -4.40% |
1 week
14.70
15.00
1 month
14.6415.46
Current year
14.6216.10
1 year
13.4217.94
3 years
12.0051.60
5 years
12.0057.00
10 years
12.0057.00
| Managers | Title | Age | Since |
|---|---|---|---|
Maciej Wieczorek
CEO | Chief Executive Officer | - | 02-06-19 |
| Investor Relations Contact | - | 17-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Rzeminski
CHM | Chairman | - | - |
| Director/Board Member | - | - | |
| Director/Board Member | 62 | 21-02-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 14.78 | -1.47% | 15,969 |
| 24-04-18 | 15 | +1.21% | 61,290 |
| 24-04-17 | 14.82 | +0.14% | 10,998 |
| 24-04-16 | 14.8 | -1.33% | 19,710 |
| 24-04-15 | 15 | 0.00% | 15,912 |
Delayed Quote Warsaw S.E., April 19, 2024 at 11:58 am EDT
More quotes
Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
14.78
PLN
Average target price
16.5
PLN
Spread / Average Target
+11.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.40% | 186M | |
| +24.60% | 654B | |
| +24.08% | 552B | |
| -5.63% | 356B | |
| +15.37% | 319B | |
| +7.38% | 295B | |
| +3.26% | 211B | |
| +0.78% | 206B | |
| -9.69% | 147B | |
| -6.63% | 144B |
- Stock Market
- Equities
- CLN Stock
